379 related articles for article (PubMed ID: 30121013)
21. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
[TBL] [Abstract][Full Text] [Related]
23. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
24. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
[TBL] [Abstract][Full Text] [Related]
25. Targeted Delivery of Doxorubicin via CD147-Mediated ROS/pH Dual-Sensitive Nanomicelles for the Efficient Therapy of Hepatocellular Carcinoma.
Qu C; Li J; Zhou Y; Yang S; Chen W; Li F; You B; Liu Y; Zhang X
AAPS J; 2018 Feb; 20(2):34. PubMed ID: 29476273
[TBL] [Abstract][Full Text] [Related]
26. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics.
Yan Z; Zhan C; Wen Z; Feng L; Wang F; Liu Y; Yang X; Dong Q; Liu M; Lu W
Nanotechnology; 2011 Oct; 22(41):415103. PubMed ID: 21914940
[TBL] [Abstract][Full Text] [Related]
27. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
28. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
29. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
[TBL] [Abstract][Full Text] [Related]
30. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
31. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
33. Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.
Zhao N; Leng Q; Woodle MC; Mixson AJ
Biochem Biophys Res Commun; 2019 May; 513(1):242-247. PubMed ID: 30954222
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy.
Maples D; McLean K; Sahoo K; Newhardt R; Venkatesan P; Wood B; Ranjan A
Int J Hyperthermia; 2015; 31(6):674-85. PubMed ID: 26185910
[TBL] [Abstract][Full Text] [Related]
35. Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer.
VanOsdol J; Ektate K; Ramasamy S; Maples D; Collins W; Malayer J; Ranjan A
J Control Release; 2017 Feb; 247():55-63. PubMed ID: 28042085
[TBL] [Abstract][Full Text] [Related]
36. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors.
Peller M; Willerding L; Limmer S; Hossann M; Dietrich O; Ingrisch M; Sroka R; Lindner LH
J Control Release; 2016 Sep; 237():138-46. PubMed ID: 27364227
[TBL] [Abstract][Full Text] [Related]
37. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
39. Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy.
Guo D; Shi C; Wang X; Wang L; Zhang S; Luo J
Biomaterials; 2017 Oct; 141():161-175. PubMed ID: 28688287
[TBL] [Abstract][Full Text] [Related]
40. A highly tumor-specific light-triggerable drug carrier responds to hypoxic tumor conditions for effective tumor treatment.
Park W; Bae BC; Na K
Biomaterials; 2016 Jan; 77():227-34. PubMed ID: 26606448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
